Sun Drug StoreSun Drug Store

Good Distribution Practice (GDP) for Pharmaceuticals, Explained

What Good Distribution Practice means, who writes the rules, and how it keeps medicines safe from the factory to the pharmacy shelf.

Back
ST
Sun Drug Store Editorial Team Editorial Team
Jun 05, 2026
Good Distribution Practice (GDP) for Pharmaceuticals, Explained

What is Good Distribution Practice (GDP) for pharmaceuticals?

Good Distribution Practice (GDP) is the set of quality standards that govern how medicines are stored, transported, and handled after they leave the manufacturer and before they reach the patient. It exists to guarantee that a product authorized by a regulator arrives at the pharmacy or hospital with its identity, strength, quality, and purity intact. In the words of the European Medicines Agency, GDP ensures the quality of a medicine is "maintained throughout the distribution network" so that authorized medicines reach the people who dispense them "without any alteration of their properties."

Manufacturing quality has its own discipline, Good Manufacturing Practice (GMP). GDP is its companion for everything afterward: receiving goods, warehousing, picking and packing, temperature management, transport, and real-world events like returns, complaints, and recalls. A perfectly made medicine can still be ruined by a hot truck, a broken seal, or a counterfeit slipped into the supply chain. GDP is the system designed to stop that, and for a buyer, understanding it is the difference between buying a product and buying assurance.

Why does GDP matter for patients and product integrity?

GDP matters because the distribution stage is where a safe product can quietly become a dangerous one, often without any visible sign. A vaccine that has frozen, an insulin pen that has cooked in a delivery van, or a tablet that has absorbed humidity may look identical to a good unit while delivering little or no therapeutic effect. The patient pays the price, and so does the institution that bought it.

The scale of the problem is documented. According to the World Health Organization, an estimated 1 in 10 medical products in low- and middle-income countries is substandard or falsified, based on more than 100 surveys covering 88 countries and roughly 48,000 samples. The WHO has estimated that countries spend around US$30.5 billion a year on these products. The failures are not limited to obscure or high-value drugs; they split almost evenly between generic and patented medicines and span everything from cancer treatments to contraceptives. A disciplined distribution chain is one of the few practical defenses against this, which is why GDP weights traceability and supply-chain integrity so heavily. For the cold-chain side of that defense, see the pharmaceutical cold chain, and for the bigger picture, see what pharmaceutical distribution is.

Who sets GDP standards? WHO, EU, MHRA, and PIC/S

There is no single global GDP rulebook, but a small set of authoritative frameworks shape almost every national regulation. They overlap heavily, which is good news for buyers: a distributor aligned with one is usually close to all of them.

  • World Health Organization (WHO). The WHO publishes model GDP guidance used as a reference by regulators worldwide, most recently as "Good storage and distribution practices for medical products" in Annex 7 of WHO Technical Report Series 1025 (2020), updating the earlier Annex 5 of TRS 957. It is the common baseline for countries building or modernizing their own rules.
  • European Union. The EU GDP guidelines, formally 2013/C 343/01, published in the Official Journal on 5 November 2013, are among the most detailed and widely copied standards. They were revised partly to implement the EU's Falsified Medicines Directive (2011/62/EU). The European Medicines Agency oversees their application across the European Economic Area.
  • MHRA (United Kingdom). The UK's Medicines and Healthcare products Regulatory Agency inspects warehouses and distributors against GDP, issues wholesale dealer licences, and publishes the widely used "Rules and Guidance for Pharmaceutical Distributors," known as the Green Guide. A central feature of the UK system is the named Responsible Person who is legally accountable for compliance.
  • PIC/S. The Pharmaceutical Inspection Co-operation Scheme harmonizes inspection standards across more than 50 participating authorities. Its GDP guide (PE 011) mirrors the EU text and helps regulators on different continents inspect to a common bar.

The ICH (International Council for Harmonisation) sits alongside these, harmonizing technical and quality expectations that underpin both manufacturing and distribution. The practical takeaway: the core expectations are remarkably consistent across all of them.

The core principles of GDP

Across the WHO, EU, MHRA, and PIC/S frameworks, GDP rests on the same load-bearing pillars. A buyer evaluating a distributor can use these as a mental checklist.

A quality management system that owns the chain

GDP starts with a documented quality management system. The distributor must define responsibilities, manage risk, control change, investigate deviations, and keep the whole operation under continuous review rather than reacting only when something breaks. The EU guidelines open with quality management precisely because everything else depends on it: written procedures, supplier and customer qualification, and a culture where problems are recorded and corrected, not hidden.

Qualified, trained personnel

People run the system, so GDP requires competent, trained staff and clear accountability. The EU and UK frameworks formalize this with the Responsible Person, an individual with the knowledge and authority to ensure GDP is followed and to make decisions about product disposition. Training is not a one-time event; it is ongoing and documented, and staff handling sensitive or controlled products need specific instruction.

Premises and storage that protect the product

Warehouses must be suitable, secure, clean, and organized so that products are protected from damage, contamination, and mix-ups. That means controlled access, pest management, segregation of returned, recalled, rejected, and expired stock, and stock rotation that respects expiry dates. Equipment used for storage and monitoring must be qualified and calibrated.

Temperature control and cold chain

Temperature is the single most failure-prone variable in pharmaceutical logistics, so GDP demands that storage areas be mapped, monitored, and kept within each product's labeled range. The EU guidelines require qualified routes and packaging, continuous temperature monitoring during transport, and recorded evidence that the chain held. For products that must stay refrigerated or frozen, this discipline is the cold chain, and a single excursion can compromise a shipment. We cover the operational detail in our guide to the pharmaceutical cold chain.

Transportation that preserves conditions

GDP extends beyond the warehouse wall. Vehicles and shipping containers must keep products within their required conditions, protect against theft and tampering, and avoid cross-contamination. Where transport is outsourced, the distributor remains responsible and must qualify and oversee its carriers rather than assuming the load is someone else's problem once it is on the road.

Documentation and traceability

If it is not documented, under GDP it did not happen. Every batch should be traceable in both directions, from supplier to customer, so that any unit can be located quickly during a recall and so that the legitimacy of each transaction can be verified. Good records are also the mechanism that keeps falsified products out: they make anomalies visible.

Handling returns, recalls, and falsified medicines

GDP requires defined procedures for the events buyers hope never happen. Returned products are assessed before any decision to return them to saleable stock. Recalls must be executable quickly and effectively, with records that show where every affected unit went. And distributors must have controls to detect and quarantine suspected falsified medicines, then report them to the competent authority. This is the explicit purpose behind the EU's combined chapter on complaints, returns, recalls, and falsified products.

What GDP means when you are choosing a supplier

For a procurement officer, GDP turns vague trust into specific, checkable questions. Does the distributor hold the relevant wholesale authorization or licence for your jurisdiction? Can they show temperature-mapping records and transport monitoring data? Do they have a named quality lead and written procedures for recalls and returns? Can they trace a batch end to end? These are reasonable things to ask, and a serious partner will answer them readily.

This is where a distributor's operating model matters. As one example, Sun Drug Store, founded in 2018 and based in Al Wakrah, Doha, imports branded pharmaceuticals and medical products from more than 12 countries into a Doha warehouse and runs its own nationwide distribution network, working with the Qatar Ministry of Public Health on registration and compliance. The point is not the brand; it is the model. Importing, marketing, and distribution under one accountable roof makes the GDP chain easier to verify than a fragmented hand-off between unrelated parties. For a structured way to evaluate options in this market, see how to choose a pharmaceutical distributor in Qatar.

Talk to us

If you are a hospital, clinic, pharmacy, or institutional buyer who needs distribution you can audit against GDP expectations, we are happy to walk through how our cold chain, documentation, and traceability work in practice. Reach the team through our contact page and we will give you straight answers.

Sources and further reading

Frequently Asked Questions

What is the difference between GMP and GDP?

Good Manufacturing Practice (GMP) covers how a medicine is made, controlling the quality of production, testing, and release at the factory. Good Distribution Practice (GDP) covers everything after that point: storage, handling, and transport up to the pharmacy or hospital. They are complementary, and a product needs both to be safe and effective by the time it reaches a patient.

Who needs to comply with GDP?

GDP applies to wholesale distributors, importers, and anyone who stores or transports medicinal products in the legal supply chain. In the EU and UK, wholesale distribution requires a formal authorization or wholesale dealer licence, and the business must name a person accountable for compliance. Manufacturers also follow GDP for the distribution activities they perform themselves.

What are the main chapters of the EU GDP guidelines?

The EU GDP guidelines (2013/C 343/01) are organized into chapters covering quality management, personnel, premises and equipment, documentation, operations, complaints and returns and recalls and falsified medicinal products, transportation, and provisions for brokers. Together these chapters define how an authorized distributor must run its quality system end to end.

How does GDP help prevent falsified medicines?

GDP requires distributors to qualify their suppliers and customers, keep full transaction records, and trace every batch in both directions, which makes it far harder for falsified products to enter unnoticed. It also mandates procedures to detect, quarantine, and report any suspected falsified medicine to the regulator. The EU guidelines were revised in part to implement the Falsified Medicines Directive for exactly this reason.

Is GDP a legal requirement in Qatar?

Medicine importation and distribution in Qatar are regulated by the Qatar Ministry of Public Health (MOPH), which oversees product registration and supply-chain compliance. While requirements are set nationally, the internationally recognized GDP principles from the WHO, EU, and PIC/S form the common quality baseline that responsible distributors operate to. Buyers should confirm that any supplier meets the applicable national requirements.

What should a buyer ask to confirm GDP compliance?

Ask for the relevant wholesale authorization or licence, evidence of temperature mapping and transport monitoring, written procedures for recalls and returns, and proof that batches can be traced end to end. Ask who the named quality or responsible person is, and how complaints and falsified-product reports are handled. A distributor that meets GDP will provide these without hesitation.